Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Gene dosage of the apolipoprotein E (APOE) epsilon 4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the epsilon 2 allele, in addition to the dose effect of the epsilon 4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of epsilon 4 alleles, risk of AD is lowest in subjects with the epsilon 2/epsilon 3 genotype, with an additional 23% of AD attributable to the absence of an epsilon 2 allele. The opposite actions of the epsilon 2 and epsilon 4 alleles further support the direct involvement of APOE in the pathogenesis of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“APOE, the major susceptibility gene for late-onset AD, has three common alleles (APOE2, 3, and 4).”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Compared to the most common APOE3/3 genotype, which is considered neutral with regard to AD risk, APOE2 is associated with a lower AD risk and older age at dementia onset, and each additional copy of APOE4 is associated with a higher risk and younger age at onset.10”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citation
Research works printed but not linked: 2
- Cornoni-Huntley, J., Blazer, D.G., Service, C. & Farmer, M.E. in Established population for epidemiologic studies of the elderly. Volume II (eds Cornoni-Huntley, J. et al.) 1–7 (NIH publication 90–495, Bethesda, 1990).
- Rothman, K.J. Modern Epidemiology. 38–39, 76 (Little, Brown & Company, Boston, 1986).
Cited by
Items 601–700 of 1,029
Deininger, M. H., Fimmen, B. A., Thal, D. R., Schluesener, H. J., & Meyermann, R. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10621.2002 · Cited by 53
“whereas the ApoE 2 genotype had a protective effect (Corder et al., 1994).”
BackgroundBrain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease
Bales, K. R. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.01.005 · Cited by 66
“…plaques comprised of deposited Ab, and neurofibrillary tangles composed of hyperphosphorylated tau in key brain areas, the most robust correlate to the memory decline that is associated with disease progression is the significant loss in the number of functional synapses (DeKosky and Scheff, 1990).”
Heertum, R. L. V., & Tikofsky, R. S. (2003) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2003.127294 · Cited by 56
Plassman, B. L., & Breitner, J. C. S. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb01377.x · Cited by 53
Goedert, M., Strittmatter, W. J., & Roses, A. D. (1994) · Nature · doi:10.1038/372045a0 · Cited by 59
Self-citationGuo, Z., Fratiglioni, L., Viitanen, M., Lannfelt, L., Basun, H., Fastbom, J., & Winblad, B. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.3.225 · Cited by 53
“It is unlikely that the lower risk associated with use of antihypertensive medication was due to the potential protective effect of the *e2 allele ( 50 ), as we found no differences in the frequencies of APOE genotypes between the two groups.”
ResultPraticò, D., Rokach, J., & Tangirala, R. K. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730736.x · Cited by 53
Vance, J. M., Farrer, L. A., Huang, Y., Cruchaga, C., Hyman, B. T., Pericak‐Vance, M. A., Goate, A. M., Greicius, M. D., Griswold, A. J., Haines, J. L., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26864 · Cited by 52
Self-citationthe CHARGE Consortium Hematology Working Group (2016) · Nature Genetics · doi:10.1038/ng.3607 · Cited by 52
Wikgren, M., Karlsson, T., Nilbrink, T., Nordfjäll, K., Hultdin, J., Sleegers, K., Broeckhoven, C. V., Nyberg, L. H., Roos, G., Nilsson, L., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.004 · Cited by 55
Salehi, A., Dubelaar, E. J. G., Mulder, M., & Swaab, D. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11445 · Cited by 52
Early Detection of Alzheimer's Disease by Combining Apolipoprotein E and Neuroimaginga
Small, G. W., Komo, S., Rue, A. L., Saxena, S., Phelps, M. E., Mazziotta, J. C., Saunders, A. M., Haines, J. L., Pericak‐Vance, M. A., & Roses, A. D. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb32600.x · Cited by 54
Self-citationLithium-responsive affective disorders: no association with the tyrosine hydroxylase gene
Cavazzoni, P. A., Alda, M., Turecki, G., Rouleau, G. A., Grof, E., Martin, R. B., Duffy, A. C., & Grof, P. (1996) · Psychiatry Research · doi:10.1016/0165-1781(96)02888-0 · Cited by 52
On the metabolism of apolipoprotein E and the Alzheimer diseases
Roses, A. D. (1995) · Experimental Neurology · doi:10.1016/0014-4886(95)90019-5 · Cited by 57
Self-citationKulminski, A. M., Culminskaya, I., Ukraintseva, S. V., Arbeev, K. G., Arbeeva, L., Wu, D., Akushevich, I., Land, K. C., & Yashin, A. I. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00689.x · Cited by 51
“These can be neurodegenerative diseases which are well known to be associated with the e4 allele (Corder et al., 1994) and are highly common at advanced ages (Bishop et al.”
BackgroundNamjoshi, D. R., Martin, G., Donkin, J., Wilkinson, A., Stukas, S., Fan, J., Carr, M., Tabarestani, S., Wuerth, K., Hancock, R. E. W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053529 · Cited by 51
Wirth, M., Pichet Binette, A., Brunecker, P., Köbe, T., Witte, A. V., & Flöel, A. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16641128 · Cited by 51
“In the MCI group, APOE "2 carriers were excluded, given the protective role of APOE "2 in AD pathology(27) and AD risk.(28) The study was approved by the Ethics Committee of the Charité University Hospital, Berlin, Germany and was in accordance with the Declaration of Helsinki.”
MethodFrom Common to Rare Variants: The Genetic Component of Alzheimer Disease
Nicolas, G., Charbonnier, C., & Campion, D. (2016) · Human Heredity · doi:10.1159/000452256 · Cited by 51
Paranjpe, M. D., Chen, X., Liu, M., Paranjpe, I., Leal, J. P., Wang, R., Pomper, M. G., Wong, D. F., Benzinger, T. L. S., & Zhou, Y. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101795 · Cited by 51
“Notably, the ApoE ε2 allele has been previously shown to have a neuroprotective effect in Alzheimer's disease (Corder et al., 1994).”
BackgroundAssociation of APOE With Primary Open-Angle Glaucoma Suggests a Protective Effect for APOE ε4
Margeta, M. A., Letcher, S. M., Igo, R. P., Cooke Bailey, J. N., Pasquale, L. R., Haines, J. L., Butovsky, O., Wiggs, J. L., & for the NEIGHBORHOOD consortium (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.61.8.3 · Cited by 51
Self-citationPetanceska, S. S., DeRosa, S., Sharma, A., Diaz, N. S., Duff, K., Tint, S. G., Refolo, L. M., & Pappolla, M. A. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:395 · Cited by 58
The Apolipoprotein E ϵ4 Allele is not Associated With Cognitive Dysfunction in Cardiac Surgery
SILBERT, B. S., Evered, L. A., Scott, D. A., & Cowie, T. (2008) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2008.04.085 · Cited by 58
Rubinsztein, D. C. (1995) · Psychological Medicine · doi:10.1017/s0033291700036138 · Cited by 51
Association of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease
Le Guen, Y., Raulin, A.-C., Logue, M. W., Sherva, R., Belloy, M. E., Eger, S. J., Chen, A., Kennedy, G., Kuchenbecker, L., O’Leary, J. P., et al. (2023) · JAMA · doi:10.1001/jama.2023.0268 · Cited by 50
Apathy and APOE in mild behavioral impairment, and risk for incident dementia
Vellone, D. A., Ghahremani, M., Goodarzi, Z., Forkert, N. D., Smith, E. E., & Ismail, Z. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12370 · Cited by 60
Alzheimer Disease: Perspectives from Epidemiology and Genetics
Haines, J. L. (2018) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110518804230 · Cited by 56
Self-citationMaezawa, I., Jin, L., Woltjer, R. L., Maeda, N., Martin, G. M., Montine, T. J., & Montine, K. S. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02818.x · Cited by 50
“Genetic linkage studies have consistently associated an increased risk of AD with inheritance of the e4 APOE allele and a decreased risk of AD with the e2 APOE allele (Corder et al. 1993; Corder et al. 1994).”
BackgroundNon-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease
Seripa, D., Panza, F., Franceschi, M., D’Onofrio, G., Solfrizzi, V., Dallapiccola, B., & Pilotto, A. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2008.12.003 · Cited by 52
Alzheimer's disease: molecular concepts and therapeutic targets
Fassbender, K. C., Masters, C. L., & Beyreuther, K. T. (2001) · Die Naturwissenschaften · doi:10.1007/s001140100237 · Cited by 61
Association of apolipoprotein ?4 allele and neuropathologic findings in patients with dementia
Martinoli, M., Trojanowski, J. Q., Schmidt, M. L., Arnold, S. E., Fujiwara, T., Lee, V. M. Y., Hurtig, H. I., Julien, J., & Clark, C. N. (1995) · Acta Neuropathologica · doi:10.1007/bf00296506 · Cited by 55
“a AD samples were also divided into two subgroups: with or without cortical LBs b Dominant clinical feature was PD c Dominant clinical feature was AD e Controls: 92 persons were > 65 years of age, 60 were > 60 years, and 92 were grandparents of unknown age [ 8 ]; 1 individual with APOE genotype ~2/~2 and 12 individual…”
BackgroundResultInfluentialWang, Y.-Y., Ge, Y.-J., Tan, C.-C., Cao, X.-P., Tan, L., & Xu, W. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201606 · Cited by 49
“By contrast, APOE2 may exert protective effects on cognitive decline and delay the onset of AD [6, 7].”
Poirier, J. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.11.012 · Cited by 53
Emerging Concepts in Acute Kidney Injury Following Cardiac Surgery
Hudson, C., Hudson, J. K. C., Swaminathan, M., Shaw, A., Stafford‐Smith, M., & Patel, U. D. (2008) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/1089253208328582 · Cited by 51
Patterns of Cortical Thickness according to APOE Genotype in Alzheimer’s Disease
Gutiérrez-Galve, L., Lehmann, M., Hobbs, N. Z., Clarkson, M. J., Ridgway, G. R., Crutch, S. J., Ourselin, S., Schott, J. M., Fox, N. C., & Barnes, J. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000258100 · Cited by 54
“Our findings, even in the absence of direct significant differences at a vertex-by-vertex level in cortical thickness among APOE e4 subgroups, suggest that e4 genotype may alter the pattern of cortical thinning related to AD. One study has found that the presence of APOE e2 may affect cortical thickness [”
ResultFernández-de-Retana, S., Cano-Sarabia, M., Marazuela, P., Sánchez-Quesada, J. L., Garcia-Leon, A., Montañola, A., Montaner, J., Maspoch, D., & Hernández-Guillamon, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15215-w · Cited by 49
Physiological and Pathological Ageing of Astrocytes in the Human Brain
Verkerke, M., Hol, E. M., & Middeldorp, J. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03256-7 · Cited by 47
Paranjpe, M. D., Belonwu, S., Wang, J. K., Oskotsky, T., Gupta, A., Taubes, A., Zalocusky, K. A., Paranjpe, I., Glicksberg, B. S., Huang, Y., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.735611 · Cited by 49
Ishizawa, K., Komori, T., Shimazu, T., Yamamoto, T., Kitamoto, T., Shimazu, K., & Hirose, T. (2002) · Acta Neuropathologica · doi:10.1007/s00401-002-0547-3 · Cited by 53
“Conversely, APOE2 is considered to be protective against AD [ 5 ].”
BackgroundAge and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study
Mosconi, L., Sorbi, S., Nacmias, B., Cristofaro, M. T. D., Fayyaz, M., Bracco, L., Herholz, K., & Pupi, A. (2004) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2003.12.005 · Cited by 51
Rea, I. M., Dowell, I. M., McMaster, D., Smye, M., Stout, R. L., & Evans, A. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00278-0 · Cited by 49
ROSES, A. D., EINSTEIN, G., GILBERT, J., GOEDERT, M., HAN, S., HUANG, D., HULETTE, C., MASLIAH, E., PERICAK‐VANCE, M. A., SAUNDERS, A. M., et al. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34413.x · Cited by 49
Self-citationChasing genes in Alzheimer?s and Parkinson?s disease
Bertoli‐Avella, A. M., Oostra, B. A., & Heutink, P. (2004) · Human Genetics · doi:10.1007/s00439-004-1097-7 · Cited by 53
Modern molecular genetic approaches to psychiatric disease
Craddock, N., & Owen, M. J. (1996) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a011558 · Cited by 49
Mann, K. M. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh199 · Cited by 48
“Furthermore, the presence of one or more 1 4 alleles decreases the age of disease onset by as much as 10 years (7).”
BackgroundThe Functions and Phenotypes of Microglia in Alzheimer’s Disease
Fujikawa, R., & Tsuda, M. (2023) · Cells · doi:10.3390/cells12081207 · Cited by 47
“While carrying the ε2 allele is protective against AD, carrying the ε4 allele is an AD risk factor for AD [29,30].”
BackgroundNichols, L. M., Masdeu, J. C., Mattay, V. S., Kohn, P., Emery, M., Sambataro, F., Kolachana, B., Elvevåg, B., Kippenhan, S., Weinberger, D. R., et al. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1893 · Cited by 48
“In contrast to the APOE ε4 allele, the APOE ε2 allele is associated with decreased risk of AD.(15,16) This genetic variant has been studied in cell and mouse models, but there has been little investigation of its effects on human brain function during cognition,(9,17) likely the result of its low prevalence.”
BackgroundHill, J. M., Bhattacharjee, P. S., & Neumann, D. M. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2006.08.001 · Cited by 56
“…hemorrhage McCarron et al. (1998) Kidney transplantation Hertzberg and Pope (2000) Low or protective e2/e2 Alzheimer's Compton et al. (2002), Corder et al. (1993, 1994), Farrer et al. (1997), Hoyt et al. (2005), Roses et al. (1995), Roses (1996), Rubinsztein and Easton (1999) HSV-1…”
BackgroundThe potential applications of Apolipoprotein E in personalized medicine
Villeneuve, S., Brisson, D., Marchant, N. L., & Gaudet, D. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00154 · Cited by 48
“…risk factor for late onset Alzheimer Disease (AD) (Poirier et al., 1993; Leduc et al., 2011; Verghese et al., 2011) with ApoE4 carriers having a 4 to 12-fold increased risk of developing AD when compared to non-carriers (Corder et al., 1993, 1994; Bertram and Tanzi, 2008; Mahley and Huang, 2012a).”
BackgroundLongitudinal progression of grey matter atrophy in non-amnestic Alzheimer’s disease
Phillips, J. S., Re, F. D., Irwin, D. J., McMillan, C. T., Vaishnavi, S., Xie, S. X., Lee, E. B., Cook, P. A., Gee, J. C., Shaw, L. M. J., et al. (2019) · Brain · doi:10.1093/brain/awz091 · Cited by 54
Candidate Gene Association Studies in Sporadic Alzheimer’s Disease
Combarros, O., Alvarez-Arcaya, A., Sánchez-Guerra, M., Infante, J., & Berciano, J. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000058332 · Cited by 54
Xu, P., Li, Y., Qin, X., Kroner, C. C., Green-Odlum, A., Xu, H., Wang, T.-Y., Schmechel, D. E., Hulette, C. M., Ervin, J. F., et al. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.06.009 · Cited by 52
“The APOE4 allele increases risk and lowers the age of onset of AD in a dose-dependent manner (Corder et al., 1994).”
BackgroundSelf-citationThe genetics of Alzheimer's disease
Rubinsztein, D. C. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00014-2 · Cited by 55
Pettigrew, C. A., Soldan, A., Zhu, Y., Cai, Q., Wang, M., Moghekar, A., Miller, M. I., Singh, B., Martinez, O., Fletcher, E. M., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.12.003 · Cited by 48
Early- and Late-Onset Alzheimer’s Disease: Two Sides of the Same Coin?
Valdez-Gaxiola, C. A., Rosales-Leycegui, F., Gaxiola-Rubio, A., Moreno-Ortíz, J. M., & Figuera, L. E. (2024) · Diseases · doi:10.3390/diseases12060110 · Cited by 64
“In previous research, it has been described that the effect of APOE ε 4 on the LOAD population reduces the age of symptom onset [132], increases disease progression, impairs cognitive function, especially episodic memory [135], is related to an increase in the regional density of A β and tau…”
BackgroundRarity of the Alzheimer Disease–Protective APP A673T Variant in the United States
Wang, L.-S., Naj, A. C., Graham, R. R., Crane, P. K., Kunkle, B. W., Cruchaga, C., Murcia, J. D. G., Cannon-Albright, L., Baldwin, C. T., Zetterberg, H., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2157 · Cited by 47
Self-citationMultimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load
Grothe, M. J., Villeneuve, S., Dyrba, M., Bartrés-Faz, D., Wirth, M., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., Weiner, M., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003585 · Cited by 47
Kim, Y. J., Seo, S. W., Park, S. B., Yang, J. J., Lee, J. S., Lee, J., Jang, Y. K., Kim, S. T., Lee, K.-H., Lee, J. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02046-y · Cited by 47
Pontifex, M., Vauzour, D., & Minihane, A.-M. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.05.017 · Cited by 47
Lakew, B., Henry, R. J., Ceccarelli, S., Grando, S., Eglinton, J. K., & Baum, M. (2012) · Euphytica · doi:10.1007/s10681-012-0674-4 · Cited by 47
“An alternative, promising approach is association mapping, which has been successfully applied in human genetics to detect quantitative trait loci (QTL) coding for simple as well as complex diseases (Corder et al. 1994; Kerem et al. 1989).”
BackgroundOyama, F., Shimada, H., Oyama, R., & Ihara, Y. (1995) · Molecular Brain Research · doi:10.1016/0169-328x(94)00233-5 · Cited by 56
Depression and dementia in relation to apolipoprotein E polymorphism in a population sample age 75+
Forsell, Y., Corder, E. H., Basun, H., Lannfelt, L., Viitanen, M. H., & Winblad, B. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00468-4 · Cited by 47
Self-citationTukhovskaya, E. A., Yukin, A. Y., Khokhlova, O. N., Murashev, A. N., & Vitek, M. P. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.21874 · Cited by 46
“In contrast, inheritance of the more frequent e3 allele, or of the rarer e2 allele, lowers the likelihood of developing AD (Corder et al., 1994; Farrer et al., 1997).”
BackgroundTargeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease
Martiskainen, H., Haapasalo, A., Kurkinen, K. M., Pihlajamäki, J., Soininen, H., & Hiltunen, M. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.789862 · Cited by 46
“Conversely, APOE "2 allele encompasses a protective effect against AD [14,15].”
BackgroundCacabelos, R., Fernández‐Novoa, L., Martínez‐Bouza, R., McKay, A., Carril, J. C., Lombardi, V., Corzo, L., Carrera, I., Tellado, I., Nebril, L., et al. (2010) · Pharmaceuticals · doi:10.3390/ph3103040 · Cited by 51
“[29] reporting an increased frequency of the APOE-4 allele in AD and the association of the APOE-4 allele with LOAD and sporadic forms of AD [26-31].”
BackgroundGiannisis, A., Al-Grety, A., Carlsson, H., Patra, K., Twohig, D., Sando, S. B., Lauridsen, C., Berge, G., Grøntvedt, G. R., Bråthen, G., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01058-9 · Cited by 46
“Carriers of the APOE ε4 allele are at a 5 to 15-fold higher risk of developing Alzheimer’s disease (AD) [15] while the APOE ε3 allele is considered AD risk-neutral and ε2 protective [16, 17].”
BackgroundGenetic complexity of Alzheimer's disease: Successes and challenges
Rogaeva, E., Kawarai, T., & George-Hyslop, P. S. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s343 · Cited by 46
“On the other hand, the frequency of the protective ε 2-allele is reduced from 10% in the normal population to 2% in AD cases [7,31].”
Nadeau, J. H., & Topol, E. J. (2006) · Nature Genetics · doi:10.1038/ng1006-1095 · Cited by 51
Alzheimers Disease - An Interactive Perspective
Heese, K., & Akatsu, H. (2006) · Current Alzheimer Research · doi:10.2174/156720506776383022 · Cited by 50
“Studies have correlated the inheritance of one or two ε4 alleles with the increased likelihood of developing AD, making its mean age of onset earlier as compared to subjects harboring ε2 and/or ε3 alleles [3-6].”
BackgroundPolymorphisms of IFS1 and IFS2 gene are associated with isoflavone concentrations in soybean seeds
Cheng, H., Yu, O. S., & Yu, D. (2008) · Plant Science · doi:10.1016/j.plantsci.2008.05.020 · Cited by 53
Xu, P.-T., Schmechel, D., Qiu, H.-L., Herbstreith, M., Rothrock-Christian, T., Eyster, M., Roses, A. D., & Gilbert, J. R. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0213 · Cited by 46
Self-citationApolipoprotein E: Depressive illness, depressive symptoms, and Alzheimer's disease
Holmes, C., Russ, C., Kirov, G., Aitchison, K. J., Powell, J. F., Collier, D. A., & Lovestone, S. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00326-0 · Cited by 47
Greenberg, B., Savage, M. J., Howland, D., Ali, S. M., Siedlak, S. L., Perry, G. L., Siman, R., & Scott, R. W. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00001-2 · Cited by 47
NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load
Pohlkamp, T., Xian, X., Wong, C. H., Durakoglugil, M. S., Werthmann, G. C., Saido, T. C., Evers, B. M., White, C. L., Connor, J., Hammer, R. E., et al. (2021) · eLife · doi:10.7554/elife.72034 · Cited by 46
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Marino, C., Perez‐Corredor, P., O'Hare, M., Heuer, A., Chmielewska, N., Gordon, H., Chandrahas, A. S., Gonzalez‐Buendia, L., Delgado‐Tirado, S., Doan, T. H., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13436 · Cited by 45
“7,8,9 APOE ε 3 occurs most frequently in 77% of the population and is by convention considered neutral regarding AD risk.”
BackgroundDowner, B. G., Estus, S., Katsumata, Y., & Fardo, D. W. (2014) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph111010663 · Cited by 54
“The APOE e4 allele is also an established risk factor for dementia, in particular Alzheimer’s disease (AD) [54], whereas as the APOE e2 allele is associated with a decreased risk for AD relative to the APOE e3 allele [55].”
BackgroundEmergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice
Hunter, J. M., Cirrito, J. R., Restivo, J. L., Kinley, R. D., Sullivan, P. M., Holtzman, D. M., Koger, D., Delong, C., Lin, S., Zhao, L., et al. (2012) · Brain Research · doi:10.1016/j.brainres.2012.05.048 · Cited by 45
Alzheimer’s disease beyond APOE
van Es, M. A., & van den Berg, L. H. (2009) · Nature Genetics · doi:10.1038/ng1009-1047 · Cited by 49
Prionoid Proteins in the Pathogenesis of Neurodegenerative Diseases
Wells, C., Brennan, S. E., Keon, M., & Saksena, N. K. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00271 · Cited by 45
Apolipoprotein E E4 Allele and Risk of Dementia
Roses, A. D. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520290026015 · Cited by 45
Self-citationActivated cAMP-response Element-binding Protein Regulates Neuronal Expression of Presenilin-1
Mitsuda, N., Ohkubo, N., Tamatani, M., Lee, Y.-D., Taniguchi, M., Namikawa, K., Kiyama, H., Yamaguchi, A., Sato, N., Sakata, K., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006153200 · Cited by 45
The Molecular Genetics of Alzheimer’s Disease
Hardy, J. A., Owen, M. J., Goate, A. M., James, L. A., Haynes, A. R., Williamson, R., Roques, P., Rossor, M. N., & Mullan, M. J. (1990) · Biomedical Advances in Aging · doi:10.1007/978-1-4613-0513-2_3 · Cited by 44
ApoE Synthesis in Human Neuroblastoma Cells
Dupont-Wallois, L., Soulié, C., Sergeant, N., Wavrant-de Wrieze, N., Chartier-Harlin, M.-C., Delacourte, A., & Caillet-Boudin, M.-L. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0155 · Cited by 47
“, 1993), whereas the e2 allele may have a protective effect (Chartier-Harlin et al., 1994; Corder et al., 1994).”
Recent Advances in the Genetics of Alzheimer's Disease
Levy‐Lahad, E., Tsuang, D. W., & Bird, T. D. (1998) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879801100202 · Cited by 50
Rao, V. S., Cupples, L. A., van Duijn, C. M., Kurz, A., Green, R. C., Chui, H. C., Duara, R., Auerbach, S. H., Volicer, L., Wells, J., et al. (1996) · PubMed Central · Cited by 56
Self-citationGenetic risk factors for Alzheimer disease: emerging roles of microglia in disease pathomechanisms
Takatori, S., Wang, W., Iguchi, A., & Tomita, T. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_5 · Cited by 44
A multi‐hit hypothesis for an APOE4 ‐dependent pathophysiological state
Steele, O. G., Stuart, A. C., Minkley, L., Shaw, K., Bonnar, O., Anderle, S., Penn, A. C., Rusted, J., Serpell, L., Hall, C., et al. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15685 · Cited by 44
“APOE4 increases LOAD risk by 2 to 8 times for heterozygotic and homozygotic carriers, relative to APOE3-carriers, respectively (Corder et al., 1993, 1994; Gureje et al., 2006; Mayeux et al., 1998; Raber et al., 2004; Saunders et al., 1993).”
BackgroundFunction and Comorbidities of Apolipoprotein E in Alzheimer′s Disease
Leduc, V., Domenger, D., De Beaumont, L., Lalonde, D., Bélanger-Jasmin, S., & Poirier, J. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/974361 · Cited by 43
“In contrast, the APOE2 variant is associated with a marked risk reduction of AD [7].”
Nielsen, H. M., Chen, K., Lee, W., Chen, Y., Bauer, R. J., Reiman, E., Caselli, R., & Bu, G. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0231-9 · Cited by 44
“The risk of developing AD is known to be higher in APOE ε3/ε4 carriers than in APOE ε2/ε4 carriers [3] and also the lipid and receptor binding capacities differ between the apoE isoforms [50].”
BackgroundSystems healthcare: a holistic paradigm for tomorrow
Fiandaca, M. S., Mapstone, M. E., Connors, E. E., Jacobson, M., Monuki, E. S., Malik, S., Macciardi, F. M., & Federoff, H. J. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0521-2 · Cited by 54
“apolipoprotein E (APOE) E4 allele, with a single genetic copy increasing the odds of developing LOAD in a normal lifetime by 2–4 times, while two allelic copies provide more than 8 times the likelihood [41].”
BackgroundMolecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Uddin, M. S., Hasana, S., Hossain, M. F., Islam, M. S., Behl, T., Perveen, A., Hafeez, A., & Ashraf, G. M. (2020) · Current Gene Therapy · doi:10.2174/1566523220666201123112822 · Cited by 64
Bartrés‐Faz, D., Junqué, C., López‐Alomar, A., Valveny, N., Moral, P., Casamayor, R., Salido, A., Bel, C., & Clemente, I. C. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.49191.x · Cited by 55
A Mathematical Model of Alzheimer's Disease and the Apoe Gene
Macdonald, A. S., & Pritchard, D. (2000) · Astin Bulletin · doi:10.2143/ast.30.1.504627 · Cited by 51
No association found between Alzheimer's disease and a mitochondrial tRNA glutamine gene variant
Wragg, M. A., Talbot, C. J., Morris, J. C., Lendon, C. L., & Goate, A. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12146-3 · Cited by 44
Genetic Epidemiology of Alzheimer Disease
Slooter, A. J. C., & van Duijn, C. M. (1997) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a017933 · Cited by 44
“Since then, numerous research groups confirmed the increased frequency of the APOE*4 allele among Alzheimer disease patients (72-97).”
BackgroundLilrB3 is a putative cell surface receptor of APOE4
Zhou, J., Wang, Y., Huang, G., Yang, M., Zhu, Y., Jin, C., Jing, D., Ji, K., & Shi, Y. (2023) · Cell Research · doi:10.1038/s41422-022-00759-y · Cited by 52
“The cDNA clones for APOE2 and APOE4 were generated by introducing the missense mutations R158C and C112R, respectively, based on the cDNA clone of APOE3.”
BackgroundResultInfluentialHigginbotham, L. A., Carter, E. K., Dammer, E. B., Haque, R. U., Johnson, E. C. B., Duong, D. M., Yin, L., Jager, P. L. D., Bennett, D. A., Felsky, D., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106286 · Cited by 43
ApoE-isoform-dependent cellular uptake of amyloid-β is mediated by lipoprotein receptor LR11/SorLA
Yajima, R., Tokutake, T., Koyama, A., Kasuga, K., Tezuka, T., Nishizawa, M., & Ikeuchi, T. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.11.111 · Cited by 43
Apolipoprotein E genotype and lifetime cognitive decline
Kozauer, N., Mielke, M. M., Chan, G., Rebok, G. W., & Lyketsos, C. G. (2007) · International Psychogeriatrics · doi:10.1017/s104161020700587x · Cited by 45
Conserved regulators of cognitive aging: From worms to humans
Arey, R. N., & Murphy, C. T. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.035 · Cited by 47
“The nitial study linking APOE to age-related phenotypes identified he 4 allele as a risk factor for the development of AD [202] hile the 2 allele is protective [35].”
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Indiana University School of Medicine (US)
- University of California, Los Angeles (US)
- Venue
- Nature Genetics
- Published
- 1994-06
- Volume
- 7
- Issue
- 2
- Pages
- 180-184
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2090271811
- Cited by
- 1,920
- References
- 41
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 78 · 2023: 59 · 2022: 66 · 2021: 76 · 2020: 76 · 2019: 58 · 2018: 62 · 2017: 58 · 2016: 75 · 2015: 55 · 2014: 63 · 2013: 68 · 2012: 66
- FWCI
- 54.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (NIA AG05128, U24AG021886)
- National Institute of Neurological Disorders and Stroke (P01NS026630, NINDS NS26630, NINDS NS531153)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, familial Alzheimer's disease, gene dosage, protective effect, sporadic Alzheimer's disease, genetic risk factors, APOE genotype
- MeSH terms
- Aged, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Humans, Male, Middle Aged, Risk Factors, Odds Ratio, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.